Pazopanib in Relapsed and Refractory Small Cell Lung Cancer
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
Investigators propose to study the single agent activity of pazopanib in a Phase II trial of
patients with relapsed or refractory small cell lung cancer. Because these patients have very
limited treatment options, use of an investigational agent in this patient population is
supported by current National Comprehensive Cancer Network guidelines. Using correlative
biologic studies to evaluate the anti angiogenic activity of pazopanib in the absence of
concomitant chemotherapy will allow us to delineate the responses due to this drug and the
effect on angiogenesis.
Pazopanib dose has been determined to 800 mg once daily per the initial recommended dose
approved by FDA and EMA, as monotherapy in advanced Renal Cell Carcinoma